Yosuke Kito

6PUBLICATIONS
12CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersMolecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Jul 06, 2026
Association of the PD-L1 CPS With the Efficacy of First-Line Nivolumab Plus Chemotherapy for Unresectable Advanced or Recurrent Gastric Cancer.

|Aug 30, 2024
Real-world treatment costs of first-line treatment for metastatic colorectal cancer: a survey of the JCOG colorectal cancer study group.

Atsuo Takashima, Megumi Ishiguro, Keita Sasaki

|Apr 06, 2024
Tumor Response Predicts Survival Time of Nivolumab Monotherapy for Advanced Gastric Cancer: A Subgroup Analysis of the DELIVER Trial (JACCRO GC-08).

Yu Sunakawa, Yasuhiro Sakamoto, Ryohei Kawabata

|Nov 11, 2023
Trifluridine/Tipiracil Plus Bevacizumab for Vulnerable Patients With Pretreated Metastatic Colorectal Cancer: A Retrospective Study (WJOG14520G).

Yosuke Kito, Hisato Kawakami, Seiichiro Mitani

|Jul 26, 2020
Phase Ib study of FOLFOXIRI plus ramucirumab as first-line treatment for patients with metastatic colorectal cancer.

Yosuke Kito, Hironaga Satake, Hiroya Taniguchi

|Jun 23, 2018
Phase II study of S-1 plus oxaliplatin 130 mg/m<sup>2</sup> in Japanese patients with advanced gastric cancer.

Yosuke Kito, Nozomu Machida, Sadayuki Kawai

Pageof 1

Frequent Collaborators

1 joint publications

Hisato Kawakami

1 joint publications

Yu Sunakawa

1 joint publications

Atsuo Takashima

1 joint publications

Keita Sasaki